Chapters Transcript Video Does monitoring pulmonary function help clinicians monitor the drug effects or, possibly, improve patient compliance? CLICK HERE FOR CME CREDIT Back to Symposium Monitoring patients who receive brinzicata, uh, of course, includes periodic assessment of possible side effects. It's not clear yet what effect the renziccata will have on patients who, uh, for instance, uh, have non-tuberculous mycobacterial lung disease. Uh, will it be associated with, uh, decreased, uh, culture positivity of, of those patients? Will it be associated with radiographic improvement? Uh, we just don't know. Uh, but I do think those are, uh, important, uh, Uh, milestones to, to keep an eye on. Now, the other is the patient's pulmonary function. Um, I think, uh, it's very important to try to establish, uh, both a baseline and, uh, any trends that occur, uh, in the pulmonary function while the patient is taking the drug. Uh, I, I don't think it's, uh, likely at all that people will have improvement, but I, I do think it's useful to demonstrate stability. Um, which might be, uh, uh, something to help patients, uh, maintain their enthusiasm about taking the drug. Created by Presenter Professor David E. Griffith, MD Professor of MedicineNational Jewish HealthDenver, Colorado, USA
